800 NMOSD patients join landmark registry to unlock disease secrets
NCT ID NCT04886492
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will follow about 800 adults with neuromyelitis optica spectrum disorder (NMOSD) across North America. Researchers will collect data on how the disease presents, progresses, and is managed in real-world settings. No experimental treatments are given; the goal is to better understand NMOSD and improve future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could reveal better ways to manage NMOSD and improve patient care.
- What could go wrong
- This is an observational study, not a treatment trial. It collects data but does not test any new therapy, so direct patient benefits are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CorEvitas, LLC
Waltham, Massachusetts, 02451, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic clues may forecast multiple sclerosis after vision loss
- Engineered immune cells take aim at autoimmune diseases
- Can virtual training rewire the brain in MS?
- New study aims to understand physical challenges in kids with nerve diseases
- Experimental CAR t treatment targets root cause of rare nerve disease
- New hope for NMOSD patients: drug aims to slash relapse rate